– FINLAND, Helsinki – Nexstim Plc (HEX: NXTMH | STO: NXTMS) today announced that its Nomination Board decided to propose the elections of Timo Hildén and Tero Weckroth as new Board members, following the announcement that Rohan Hoare, a Board member since 2016, and Tomas Holmberg, a Board member since 2017, will no longer be available to the Board of Directors for the period 2021-2022.
“I am truly delighted that Timo Hildén and Tero Weckroth have made themselves available as members of the Board of Directors of Nexstim. They are both known for their deep and diverse expertise in the health technology and pharmaceutical industries: Timo Hildén has truly extensive experience in the medical and health technology field at both the operational and management team and board levels. Tero Weckroth is a professional in the pharmaceutical industry who has also worked in the international financial sector for a long time. Against this background, they would both be able to brilliantly support Nexstim’s growth into an increasingly significant international company.” said Board Chair, Leena Niemistö.
She added: “At the same time, I warmly thank Rohan Hoare and Tomas Holmberg for their long-term work on the Board of Nexstim. I wish them all the best for the future.”
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus. It is a navigated transcranial magnetic stimulation technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus technology is used in Nexstim’s proprietary Navigated Brain Therapy system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.
Also, Nexstim is commercializing its SmartFocus based Navigated Brain Stimulation system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information: https://www.nexstim.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
